Convalescent Plasma Therapy for Persistent Hepatitis E Virus Infection
Persistent hepatitis E virus (HEV) infection is recognised in immunocompromised patients, particularly solid organ transplant (SOT) recipients [1]. The majority of cases are caused by genotype 3 (G3) HEV [1]. Ribavirin monotherapy is considered first-line when the reduction of immunosuppression is contraindicated or unsuccessful [2]. Treatment failure and relapse is recognised with limited alternative treatment options [3]. Current guidelines suggest re-treatment with a prolonged course of ribavirin or, in cases of intolerance or non-response, PEG-Interferon (if not contraindicated) [2,4].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Michael Ankcorn, Jennifer Gallacher, Samreen Ijaz, Yusri Taha, Heli Harvala, Sheila Maclennan, Emma C. Thomson, Chris Davis, Joshua B Singer, Ana da Silva Filipe, Katherine Smollett, Marc Niebel, Malcolm G. Semple, Richard S. Tedder, Stuart McPherson Tags: Letter to the Editor Source Type: research